BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27431203)

  • 1. Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.
    Mikuła-Pietrasik J; Uruski P; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
    Med Oncol; 2016 Aug; 33(8):94. PubMed ID: 27431203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.
    Mikuła-Pietrasik J; Uruski P; Matuszkiewicz K; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
    Cell Oncol (Dordr); 2016 Oct; 39(5):473-481. PubMed ID: 27444787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant ascites determine the transmesothelial invasion of ovarian cancer cells.
    Mikuła-Pietrasik J; Uruski P; Szubert S; Szpurek D; Sajdak S; Tykarski A; Książek K
    Int J Biochem Cell Biol; 2017 Nov; 92():6-13. PubMed ID: 28888784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Proangiogenic Capabilities of Malignant Ascites Generated by Aggressive Ovarian Tumors.
    Mikuła-Pietrasik J; Uruski P; Szubert S; Maksin K; Moszyński R; Szpurek D; Woźniak A; Sajdak S; Tykarski A; Książek K
    Biomed Res Int; 2017; 2017():2592496. PubMed ID: 29085834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
    Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
    Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
    Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
    Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
    Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
    Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines in peritoneal fluid of ovarian neoplasms.
    de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
    J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.
    Rudlowski C; Pickart AK; Fuhljahn C; Friepoertner T; Schlehe B; Biesterfeld S; Schroeder W
    Int J Gynecol Cancer; 2006; 16 Suppl 1():183-9. PubMed ID: 16515588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper content in ascitic fluid is associated with angiogenesis and progression in ovarian cancer.
    Onuma T; Mizutani T; Fujita Y; Yamada S; Yoshida Y
    J Trace Elem Med Biol; 2021 Dec; 68():126865. PubMed ID: 34601284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant Ascites Promote Adhesion of Ovarian Cancer Cells to Peritoneal Mesothelium and Fibroblasts.
    Uruski P; Mikuła-Pietrasik J; Pakuła M; Budkiewicz S; Drzewiecki M; Gaiday AN; Wierzowiecka M; Naumowicz E; Moszyński R; Tykarski A; Książek K
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
    Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
    Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Epithelial-Mesenchymal Transition Initiated by Malignant Ascites Underlies the Transmesothelial Invasion of Ovarian Cancer Cells.
    Pakuła M; Mikuła-Pietrasik J; Witucka A; Kostka-Jeziorny K; Uruski P; Moszyński R; Naumowicz E; Sajdak S; Tykarski A; Książek K
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
    Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
    Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Significance of Peptidome in Human Ovarian Cancer for Patients With Ascites.
    Huang X; Zhou J; Tang R; Han S; Zhou X
    Int J Gynecol Cancer; 2018 Feb; 28(2):355-362. PubMed ID: 29240604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
    Wilhelm S; Schmitt M; Parkinson J; Kuhn W; Graeff H; Wilhelm OG
    Int J Oncol; 1998 Oct; 13(4):645-51. PubMed ID: 9735390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo.
    Mikuła-Pietrasik J; Sosińska P; Naumowicz E; Maksin K; Piotrowska H; Woźniak A; Szpurek D; Książek K
    Clin Exp Metastasis; 2016 Jan; 33(1):15-27. PubMed ID: 26433963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalization of the ovarian cancer microenvironment by SPARC.
    Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
    Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways.
    Pourgholami MH; Ataie-Kachoie P; Badar S; Morris DL
    Gynecol Oncol; 2013 Apr; 129(1):113-9. PubMed ID: 23274564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.